Medtronic launches deep brain implant for epileptic seizures by Conor Hale Wednesday, February 20, 2019 The medtech giant has begun rolling out its therapy in the U.S., with the treatment of its first commercially implanted patient.
Axovant spins out its epilepsy drug team with $100M lined up by Conor Hale Thursday, February 14, 2019 Axovant spun off its small molecule team into Arvelle Therapeutics, as it continues its march toward a sole focus on gene therapies.
New discoveries in hematology and epilepsy—News of Note by Arlene Weintraub Monday, December 3, 2018 The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
Solving an old neuroscience puzzle may lead to epilepsy therapy by Angus Liu Friday, November 9, 2018 Discovery made by Virginia Tech scientists on perineuronal nets could open up new approach for acquired epilepsy.
Backed by Bain, Pfizer loads prime CNS assets into new biotech by Phil Taylor Tuesday, October 23, 2018 Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel.
Supernus adds epilepsy drug via $185M Biscayne buy by Phil Taylor Friday, September 14, 2018 Supernus makes a return to epilepsy R&D, buying the developer of a traditional Chinese medicine-derived drug for $15 million upfront.
Xenon frees itself of some XEN1101 milestone obligations by Nick Paul Taylor Tuesday, September 11, 2018 The agreement sees Xenon pay $6 million upfront to avoid having to hand over up to $40 million in milestones plus royalties down the line.
Xenon adds discontinued GSK drug to epilepsy pipeline by Amirah Al Idrus Thursday, September 6, 2018 Xenon Pharmaceuticals is taking a stab at repurposing GlaxoSmithKline's ezogabine for a rare, difficult-to-treat form of pediatric epilepsy.
